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Polymorphisms in the transcription factor Stat4 gene have
been implicated as risk factors for systemic lupus
erythematosus. Although some polymorphisms have a
strong association with autoantibodies and nephritis, their
impact on pathophysiology is still unknown. To explore
this further we used signal transducers and activators of
transcription 4 (Stat4) knockout MRL/MpJ-Faslpr/Faslpr (MRL-
Faslpr) mice and found that they did not differ in survival or
renal function from Stat4-intact MRL-Faslpr mice. Circulating
interleukin (IL)-18 levels, however, were elevated in Stat4-
deficient compared to Stat4-intact mice, suggesting that this
interleukin might contribute to the progression of lupus
nephritis independent of Stat4. In a second approach, Stat4
antisense or missense oligonucleotides or vehicle were given
to MRL-Faslpr mice with advanced nephritis. Each of these
treatments temporarily ameliorated disease, although IL-18
was increased in each setting. Based on these findings,
studies using gene transfer to overexpress IL-18 in MRL-Faslpr
and IL-12p40/IL-23 knockout MRL-Faslpr mice reveal a critical
role for IL-18 in mediating disease. Thus, the Stat4 and IL-12
(an activator of Stat4)-independent factor, IL-18, can drive
autoimmune lupus nephritis in MRL-Faslpr mice. Temporarily
blocking Stat4 during advanced nephritis ameliorates
disease, suggesting a time-dependent compensatory
proinflammatory mechanism.
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Systemic lupus erythematosus (SLE) is an autoimmune
disease that involves increased production of autoantibodies,
immune complex deposition in various organs, complement
activation, and leukocyte infiltration. Until now the major
cause of disease initiation remains unknown. The role of
genetics in disease development is controversial. In addition
to some widely known hereditary functional disorders
regarding the early components of the classical complement
pathway (complement 1q, complement 1r/complement 1s,
complement 4, or complement 2),1 numerous susceptibility
loci for SLE have been identified in the last years. Recently,
polymorphisms in the Stat4 gene have been described as risk
factors for SLE.2 Several of the polymorphisms showed a
strong association with double-stranded DNA autoantibo-
dies, nephritis, early age of diagnosis,3 and lower interferon
(INF)-a activity in peripheral blood mononuclear cells in
SLE patients.4 However, the impact of these polymorphisms
on the functions of the immune system and the patho-
physiology of SLE remain unknown.
Stat4 was first isolated in 19945,6 and its expression is
restricted in myeloid cells, thymus, and testis.6 In the resting
human T cells, Stat4 expression is low, however, expression
can be upregulated by activation with phytohemagglutinin.
Stat4 is predominantly activated by interleukin (IL)-127 and
Stat4-deficient mice showed an impaired Th1 differentiati
on with reduced INF-g production and an impaired
cell-mediated immune response (8, Ivashkiv, 2004 #18).
Stat4-deficient lymphocytes showed an impaired response to
IL-12, with a reduced proliferative response.8 In numerous
studies, the role of cytokines, especially that of INF-g, IL-12,
and IL-18, has been intensively investigated in mouse models
for SLE disease development. The MRL/MpJ-Faslpr/Faslpr
(MRL-Faslpr) mouse is a model of SLE characterized by many
clinical (for example, glomerulonephritis, arthritis) and
immunological features (for example, autoantibody forma-
tion) similar to human SLE.9
Renal injury in MRL-Faslpr mice is complex and consists
of glomerular, interstitial, and perivascular disease mediated
by immune complex deposition and infiltration of
monocytes and lymphocytes. INF-g is crucial for disease
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development and drives the autoimmune kidney destruction
in MRL-Faslpr(ref. 10). IL-12 is important for the regulation of
INF-g production, and IL-12 secreted by renal tubular
epithelial cells (TECs) has been shown to promote the
autoimmune kidney destruction by expanding IFN-g-secret-
ing T cells.11,12 IL-18, another potent IFN-g-inducing
cytokine expressed by TECs and mononuclear cells, is related
to the IL-1 family in terms of its structure, receptor family,
and function (see below).13 IL-18 is involved in Th1 clone
development and IFN-g production in T cells and therefore
involved in inflammatory and autoimmune disorders.13,14
The importance of IL-18 in the lupus-like syndrome of MRL-
Faslpr mice was demonstrated in a study showing that the
overexpression of an IL-18 receptor accessory chain (IL-
18Rb) on lymphocytes from MRL-Faslpr mice could account
for the hyperresponsiveness of these cells to IL-18, resulting
in enhanced IFN-g secretion.15 Furthermore, a correlation of
tubular IL-18 expression and disease activity could be
shown.16 Thus, IL-18 has many functional properties that
are similar to that of IL-12. In mice deficient for IL-18, IFN-g
production was suppressed despite the presence of IL-12.17
These data suggest that there is an important interplay
between IL-12 and IL-18 for optimal IFN-g production.
Although functionally similar, differences in the down-
stream signaling pathway of IL-12 and IL-18 receptors have
been reported.18 In contrast to IL-18, IL-12 is an important
activator of Stat4 and signals via the receptor-associated
Janus kinases, Janus kinases 2 and TYK2.19 Thus, although
IL-12 and IL-18 seem to act synergistically, they use
independent pathways of intracellular signaling.
In the present study, we report that targeting Stat4 in
severe lupus nephritis reveals compensatory proinflamma-
tory mechanisms proven by two approaches: the knockout
approach of Stat4 gene and the knockdown approach of the
Stat4 mRNA. Knocking out the Stat4 gene does not affect
clinical features compared with wild-type (WT) mice,
whereas treatment with antisense (AS) oligonucleotides for
a period of 3 weeks ameliorates the advanced lupus nephritis
in MRL-Faslpr mice. Interestingly, we show that IL-18
functions independently of IL-12 to incite kidney injury in
MRL-Faslpr mice. We conclude that the compensatory
upregulation of IL-18 in the Stat4 knockout approach
mediates kidney disease in MRL-Faslpr mice. However, the
AS oligonucleotide treatment to knock down Stat4 tempora-
rily during advanced renal injury resulted in an amelioration
of kidney diseases.
RESULTS
Nephritis, systemic disease, and survival are not altered
in Stat4/MRL-Faslpr mice
To evaluate the relevance of Stat4 in initiation and
acceleration of kidney and systemic disease in MRL-Faslpr
mice, we generated Stat4/MRL-Faslpr mice.
We did not detect a difference in the survival of Stat4/
MRL-Faslpr mice compared with WT mice (Figure 1a).
Furthermore, we did not determine a difference in
lymphadenopathy and splenomegaly in Stat4/ compared
with Stat4þ /þMRL-Faslpr mice (data not shown) and renal
damage (renal function; Figure 1b). The severity of
glomerular, interstitial, and perivascular pathologies
was similar in Stat4/ and Stat4þ /þMRL-Faslpr mice (data
not shown). Similarly, there was no difference in the number
of infiltrating leukocytes (CD4þ , CD8þ , CD45/B220þ , and
F4/80þ cells; Figure 1c). However, we detected significantly
higher serum levels of IL-18 and IL-12, but no difference in
INF-g serum levels in Stat4/ compared with Stat4þ /þ
MRL-Faslpr mice (Figure 1d). The analysis of immunoglo-
bulin (Ig) G subclasses revealed significantly higher serum
titres of IgG1 in Stat4/ mice, whereas serum levels of
IgG2a, IgG2b, and IgG3 showed comparable values in Stat4/
and Stat4þ /þMRL-Faslpr mice (Figure 1e). Taken together,
deletion of Stat4 did not result in an improvement of renal
disease in Stat4/MRL-Faslpr mice. However, we detected a
compensatory upregulation of IL-18 and IL-12 in Stat4/
MRL-Faslpr mice, suggesting that IL-18 independent of IL-12-
Stat4 signaling mediates kidney injury.
AS oligonucleotides are potent inhibitors of IL-12-induced
INF-c production
To confirm the efficacy of oligonucleotide treatment,
splenocytes from Balb/c Stat4þ /þ mice were stimulated
with IL-12, resulting in a significant increase in INF-g
production (Figure 2). After co-incubation with IL-12 and
AS oligonucleotides, the level of INF-g was markedly reduced
than stimulation with IL-12 alone. Co-stimulation with IL-12
and anti-IL-18 showed decreased INF-g levels than stimula-
tion with IL-12. Thus, AS oligonucleotides are capable of
sufficient inhibition of IL-12-induced INF-g production.
Stat4 blockade temporarily ameliorates advanced
kidney and systemic disease in MRL-Faslpr mice
To determine whether Stat4 modulates disease activity and
progression, we treated MRL-Faslpr mice at 5 months of age
with severe kidney and systemic disease using Stat4 AS
oligonucleotides compared with mice treated with missense
(MS) oligonucleotides and phosphate-buffered saline for
control. After 3 weeks of treatment, renal function was
improved in AS oligonucleotide-treated compared with
MS oligonucleotide-treated MRL-Faslpr mice, as determined
by proteinuria, blood urea nitrogen (BUN), and creatinine
(Figure 3a).
In correlation to our clinical findings, we detected less
glomerular damage (Figure 3b) and a decreased number of
infiltrating leukocytes in kidneys of AS oligonucleotide-
treated vs MS oligonucleotide-treated MRL-Faslpr mice
(Figure 3c). Immunostaining revealed a tendency to a lower
number of CD4þ infiltrating cells glomerularly and inter-
stitially. Furthermore, a significantly lower number of
glomerular and interstitial F4/80þ , CD8þ , and CD45/
B220þ cells could be found in mice treated with AS
oligonucleotides compared with MS oligonucleotide-treated
mice or controls (Figure 3c). As expected from our in vitro
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experiments, we detected decreased INF-g levels following AS
oligonucleotide treatment compared with MS oligonucleo-
tide-treated and control MRL-Faslpr mice (AS: 20.3±16.3;
MS: 36.3±10.5; controls: 26.3±26.3 pg/ml). Surprisingly,
we found significantly higher levels of IL-18 in mice
treated with AS oligonucleotides compared with mice MS
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Figure 1 |Nephritis, systemic disease, and survival are not altered in MRL/MpJ-Faslpr/Faslpr (MRL-Faslpr) Stat4/ mice. (a) There
are no differences in survival between MRL-FaslprStat4þ /þ and Stat4/ mice. (b) Proteinuria, blood urea nitrogen (BUN), and creatinine did
not show differences between MRL-FaslprStat4þ /þ and Stat4/mice. (c) Interstitial infiltration is similar in MRL-FaslprStat4þ /þ and Stat4/
at 5 months of age. Representative photomicrograph of F4/80þ cells; top panel: interstitial, bottom panel: glomeruli (magnification  40).
(d) Serum levels of interleukin (IL)-18 and IL-12 are increased in MRL-FaslprStat4/ compared with Stat4þ /þ mice. (e) MRL-FaslprStat4/
mice showed significantly higher levels of immunoglobulin (Ig) G1 compared with Stat4þ /þ mice. Values are mean±s.e.m.
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oligonucleotide- or phosphate-buffered saline-treated mice
(Figure 3d). Treatment with AS or MS oligonucleotides had
no significant effect on serum levels of IgG and its subclasses.
The role of IgGs in mediating kidney and systemic disease
is discussed controversially; our findings would support the
concept that the extent of circulating IgGs and auto-
antibodies does not exclusively correlate with kidney
damage.20,21 In conclusion, Stat4 knockout did not affect
the disease initiation and acceleration, whereas temporary
treatment with AS oligonucleotides ameliorates the disease
activity and progression in MRL-Faslpr mice.
Co-incubation with AS oligonucleotides and anti-IL-18
greatly suppresses spontaneous INF-c production in
splenocytes, but Stat4/ mice achieve the IFN-c
production through IL-18 expression
To clarify the underlying mechanisms of our in vivo
approach, we investigated the INF-g production in spleno-
cytes isolated from MRL-Faslpr mice. Incubation with IL-12
led to very high levels of INF-g production (Figure 4a). By
comparison, IL-12-induced INF-g production in splenocytes
of MRL-Faslpr mice treated with AS oligonucleotides was
greatly reduced, and not affected by MS treatment. Interest-
ingly, splenocytes of MRL-Faslpr mice showed a higher
baseline production of INF-g compared with BALB/c mice.
Stimulation with AS oligonucleotides and anti-IL-18 was able
to reduce INF-g production below baseline levels compared
with stimulation with AS oligonucleotides alone. In conclusion,
Stat4-signaling and IL-18 appear to be the most potent mediators
of INF-g production.
Using splenocytes of MRL-Faslpr Stat4/ and Stat4þ /þ
mice, we determined that the INF-g production in response
to IL-18 was comparable in MRL-Faslpr Stat4/ and
Stat4þ /þ mice. Moreover, following stimulation with
IL-12, IL-18 production in MRL-Faslpr was independent of
Stat4. In addition, the IFN-g and IL-18 expression could
be blocked by anti-IL-18 treatment. Thus, the in vitro data
support the importance of IL-18 in initiation and progression
of lupus nephritis in MRL-Faslpr.
Gene transfer of IL-18 into MRL-Faslpr kidneys induced
nephritis
On the basis of the results in MRL-Faslpr Stat4/ mice and
AS oligonucleotide treatment, we evaluated the relevance of
IL-18 during kidney disease in MRL-Faslpr mice by over-
expressing IL-18 locally in the kidney of MRL-Faslpr mice
using ‘IL-18-carrier cells’. ‘IL-18-carrier cells’ constitutively
secrete high levels of IL-18 in culture as compared with
‘carrier cells’ (Figure 5a). Furthermore, we confirmed
successful gene transfer of IL-18 into MRL-Faslpr TECs by
the presence of EGFP (Figure 5a). Of note, in the IL-18
overexpression study, we analyzed mice at day 28 after
‘carrier cell’ implantation, unless otherwise stated. Intrarenal
IL-18 transcripts increased following ‘IL-18-carrier cell’
implantation as compared with ‘carrier cell’ implantation
and untreated kidneys at 3 months of age (Figure 5a, right
panel). Following intrarenal IL-18 overexpression, we de-
tected massive accumulation of leukocytes within the implant
site that extended into the adjacent intrarenal area (Figure
5b). Furthermore, we detected a notable increase in
glomerular and tubular damage following ‘IL-18-carrier cell’
compared with ‘carrier cell’ implantation (Figure 5b). The
increase in kidney pathology is accompanied by accumula-
tion of multiple leukocyte populations in the kidney
following ‘IL-18-carrier cell’ compared with ‘carrier cell’
implantation (Figure 5c). To determine whether the increase
in renal pathology and intrarenal leukocytes following
overexpression of IL-18 was accompanied by impaired renal
function, we compared proteinuria and serum BUN levels.
In fact, proteinuria and BUN levels rose in mice following
‘IL-18-carrier cell’ compared with ‘carrier cell’ implantation
to levels comparable to that of nephritic MRL-Faslpr mice at
5 months of age. Thus, intrarenal overexpression of IL-18
initiates kidney disease in MRL-Faslpr mice.
Increasing intrarenal IL-18 initiates systemic disease in
MRL-Faslpr mice
To determine whether intrarenal IL-18 expression could be
responsible for systemic disease in MRL-Faslpr mice, we
assessed several cytokines in the circulation, as well as the
impact of IL-18 overexpression on contralateral kidney
and lung pathology. We detected a rise in circulating IL-18,
IFN-g, and tumor necrosis factor-a following intrarenal
‘IL-18-carrier cell’ compared with ‘carrier cell’ implantation
(Figure 6a) that are comparable to levels detected in MRL-
Faslpr mice with advanced kidney disease (data not shown).
Interestingly, other pro-inflammatory cytokines, such as
IL-12 and IL-1b, were not affected by the intrarenal IL-18
overexpression. To establish whether these enhanced cytokine
levels were a reflection of accelerated systemic disease, we
evaluated intrarenal leukocytes in the contralateral kidney.
Interestingly, we detected an increase of multiple leukocyte
populations in the contralateral kidney following ‘IL-18-
carrier cell’ compared with ‘carrier cell’ implantation (Figure 6b).
Moreover, we could detect an accumulation of perivascular
and interstitial leukocytes in the lung following intrarenal
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Figure 2 |Antisense (AS) oligonucleotides inhibit the
interferon (IFN)-c expression in splenocytes of BALB/c Stat4þ /þ
mice. Interleukin (IL)-12 induces INF-g production in splenocytes
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‘IL-18-carrier cell’ compared with ‘carrier cell’ implantation
(intrapulmonary 2.25±0.89 vs 1.17±0.41, *Po0.05; peri-
vascular 2.75±0.46 vs 1.83±0.75, *Po0.05; peribronchial
2.63±0.52 vs 2.00±0.63). Thus, the rise in the level of
circulating cytokines and increased leukocyte infiltration in
the contralateral kidney and lung suggests that local
intrarenal IL-18 expression initiates systemic disease in
MRL-Faslpr mice.
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IL-18 elicits renal injury independent of IL-12 and/or IL-23
in MRL-Faslpr mice
To clarify whether the presence of IL-12 and/or IL-23
is required for the IL-18 induced nephritis, we implanted
‘IL-18-carrier cells’ into IL-12p40/IL-23/ and intact
MRL-Faslpr mice. We detected a comparable influx of
leukocytes in IL-12p40/IL-23/ and MRL-Faslpr mice
assessed at the implantation site, periglomerular, perivascu-
lar, and interstitial (Figure 7a). Furthermore, circulating
IL-18 and IFN-g levels were increased whereas level of IL-12
was not detectable (data not shown). The increase in
intrarenal leukocytes in IL-12p40/IL-23/ and MRL-Faslpr
was accompanied by impaired renal function. Proteinuria
and BUN levels rose to levels comparable to nephritic
MRL-Faslpr mice at 5 months of age (Figure 7b). Thus, IL-18
initiates and accelerates kidney disease in MRL-Faslpr mice
independent of IL-12p40 and/or IL-23.
DISCUSSION
In the present study, we dissected the role of Stat4 on lupus
nephritis by two approaches. Stat4 gene deletion does not
affect disease initiation and progression in MRL-Faslpr
compared with WTmice, whereas temporary treatment with
AS oligonucleotides ameliorates advanced lupus nephritis in
MRL-Faslpr mice. On the basis of the finding that in both
approaches a compensatory IL-18 upregulation was detect-
able, studies using gene transfer to overexpress IL-18 in MRL-
Faslpr and IL-12p40/IL-23/MRL-Faslpr mice reveal a critical
role for IL-18 in mediating kidney and systemic disease in
MRL-Faslpr mice.
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Figure 4 | Stat4, interleukin (IL)-12, and IL-18 are potent inducers of interferon (IFN)-c in splenocytes of MRL/MpJ-Faslpr/Faslpr
(MRL-Faslpr) Stat4þ /þ and Stat4/ mice. (a) Following stimulation with IL-12, administration of antisense (AS) oligonucleotides was
effective in blocking INF-g production. Unstimulated splenocytes of MRL-Faslpr mice showed a high baseline production of IFN-g.
This baseline production is reduced by the administration of AS oligonucleotides and can be reduced even further by co-incubation with
AS oligonucleotides and anti-IL-18. (b) Moreover, IFN-g and IL-18 production in MRL-FaslprStat4þ /þ were comparable to levels in
MRL-FaslprStat4/ mice. Values are mean±s.e.m.
Figure 3 |Antisense (AS) treatment for 3 weeks in MRL/MpJ-Faslpr/Faslpr (MRL-Faslpr) mice with advanced renal disease ameliorate
kidney disease temporarily while interleukin (IL)-18 is compensatorily upregulated. (a) Mice treated with AS oligonucleotides showed
less proteinuria and tended towards decreased serum blood urea nitrogen (BUN) and creatinine levels compared with control (phosphate-
buffered saline treated) and missense (MS)-treated mice. (b) Mice treated with AS oligonucleotides showed reduced glomerular pathology.
Representative photomicrographs of pathology are shown for glomerular, interstitial, and perivascular area. (c) AS treatment led to a
reduced number of glomerular CD4þ , CD8þ , or F4/80þ cells (intraglomerular and periglomerular) and interstitially compared with MS and
control-treated mice. (d) Serum levels of interferon (INF)-g were significantly lower in mice treated with AS oligonucleotides compared with
controls. Serum levels of IL-18 were significantly higher in mice treated with AS oligonucleotides compared with MS oligonucleotides and
controls, while IL-12 levels were unaffected. Values are mean±s.e.m.
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In MRL-Faslpr mice, INF-g deficiency led to the absence of
lupus disease,10 as well as in NZB/NZWmice, another mouse
model for lupus.22 In experiments using a mouse model for
SLE based on NZB/NZWmice, Stat4/ New Zealand mixed
mice developed accelerated kidney disease with an increase in
proteinuria and mortality despite decreased IFN-g serum
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Figure 5 | Intrarenal overexpression of interleukin (IL)-18 incites nephritis in MRL/MpJ-Faslpr/Faslpr (MRL-Faslpr) mice. (a) Left panel:
successful gene transfer of IL-18 using a retroviral expression system. IL-18 concentrations in the supernatant of ‘IL-18-carrier cells’/‘carrier cells.’
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histopathology is increased following ‘IL-18-carrier cell’ compared with ‘empty vector carrier cell’ at day 28 post implantation. We evaluated the
enhanced accumulation of infiltrating leukocytes extending from the subcapsular site to the renal cortex and the intrarenal pathology.
Representative microphotographs of the implantation site are shown, magnification  20. (c) Leukocytes are increased at the site of
implantation and intrarenal following ‘IL-18-carrier cell’ compared with ‘carrier cell’ implantation, evaluated by immunostaining for T cells
(CD4þ , CD8þ , and B220þ ) and Mø (F4/80þ ). (d) Loss of renal function is accelerated following ‘IL-18-carrier cell’ in comparison with ‘empty
vector carrier cell’ implantation in MRL-Faslpr mice. We evaluated renal function by measuring (1) proteinuria semi-quantitatively, (2) serum blood
urea nitrogen (BUN); dotted line is BUN levels in MRL-Faslpr (5 months of age) controls. Data are the mean±s.e.m.
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levels.23,24 In contrast, administration of exogenous IFN-g
accelerates renal disease in (NZBNZW)F1 mice. Surpris-
ingly, we did not detect any amelioration or acceleration of
lupus disease in MRL-FaslprStat4/ mice, moreover, Stat4
deficiency had no impact on INF-g production. These
differences between MRL-Faslpr and NZB/NZW mice could
be explained by the different role of type I IFNs in these
models: in NZB/NZWmodels, type-I IFN receptor deficiency
reduced lupus-like disease,25 whereas the type I IFN, IFN-b,
turned out to be therapeutic in MRL-Faslpr mice.26 In human
SLE patients, Stat4 polymorphisms were recently described in
patients who showed decreased IFN-a activity in peripheral
blood mononuclear cells but increased expression of IFN-a-
induced genes.4 Stat4 showed a dominant influence on the
sensitivity of peripheral blood mononuclear cells to serum
IFN-a and seems to be an important mediator in type-I IFN
pathway.
In fact, Stat4 deficiency does not mediate initiation of
lupus nephritis in MRL-Faslpr mice. Thus, we speculated that
different cytokines might be responsible for this observation
and we focused on IL-18. We choose to focus on IL-18 as
lymphocytes from MRL-Faslpr mice have been shown to be
hyperresponsive to IL-18, resulting in enhanced IFN-g
secretion.
The importance of IL-18 in the lupus-like syndrome of
MRL-Faslpr mice was demonstrated in a study showing that
lymphocytes of MRL-Faslpr mice are hyperresponsive to
IL-18, which results in enhanced IFN-g secretion.15 Further
support for the concept of IL-18 as a sufficient inducer of a
TH1 response comes from recent studies in our lab on
overexpression and blocking of IL-18. Local intrarenal
overexpression of IL-18 incites lupus nephritis and systemic
disease, a blockade of IL-18 activation ameliorates kidney and
systemic disease (manuscript submitted). IL-18 receptor-
a-deficient MRL-Faslpr mice have markedly reduced auto-
immune disease,27 and IL-18 complementary DNA vaccination
protects MRL-Faslpr mice from spontaneous lupus-like
autoimmune disease.28 Furthermore, IL-18-deficient mice
show an ameliorated kidney disease in a model of induced
autoimmune nephritis (nephrotoxic serum nephritis).29
In addition, it has been shown that tubular IL-18 expression
correlates with disease activity in MRL-Faslpr mice.16 We
found elevated levels of IL-18 in MRL-FaslprStat4/ mice
and, therefore, we speculate that IL-18 bypasses the Stat4
gene defect in MRL-FaslprStat4/ mice and leads to similar
levels of INF-g compared with WT. The results of our in vitro
approach support that both Stat4 and IL-18 contribute to
spontaneous INF-g production and that IL-18 works
independently of IL-12 to promote a sufficient IFN-g
production to mediate disease.
Bearing in mind the limitations of performing studies in
gene-targeted mice,30 we used AS oligonucleotide treatment
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Figure 6 | Intrarenal overexpression of interleukin (IL)-18 initiates systemic disease in MRL/MpJ-Faslpr/Faslpr (MRL-Faslpr) mice.
(a) Serum IL-18, interferon (IFN)-g, IL-12, IL-1b, and tumor necrosis factor (TNF)-a levels in MRL-Faslpr following ‘IL-18-carrier cell’ compared
with ‘carrier cell’ implantation determined by enzyme-linked immunosorbent assay. (b) We evaluated the number of intrarenal Mø
(F4/80þ ) and T cells (CD4þ , CD8þ , B220þ ) in MRL-Faslpr following ‘IL-18-carrier cell’ compared with ‘carrier cell’ implantation at 3 months
of age. Values are mean±s.e.m.
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as a posttranscriptional modification of gene expression
to knock down Stat4 in vivo. We found that AS oligo-
nucleotide therapy resulted in an amelioration of advanced
kidney disease. This technique offers a realistic option as
a therapeutic treatment in human SLE patients. AS oligo-
nucleotides have mainly been tested in the field of oncology
in phase II and III studies. A combination with oblimersen
sodium, a Bcl-2 AS oligonucleotide, and rituximab was
shown to be effective in patients with recurrent B-cell non-
Hodgkin’s lymphoma.31 In contrast, aprinocarsen, a protein
kinase C-alpha AS oligonucleotide, did not enhance survival
and other efficacy measures in patients with advanced
non-small cell lung cancer treated with gemcitabine and
cisplatin.32 Future studies will likely prove the efficacy of AS
oligonucleotide treatment and give a rationale for the
application in patients with autoimmune disease.
In the present study, treating MRL-Faslpr mice for 3 weeks
resulted in the amelioration of lupus nephritis. However, we
also observed a concomitant increase in serum levels of IL-18.
One possibility for the differing effect of the inhibition of
Stat4 signaling is the time of blockade. The increased levels
of IL-18 in the AS oligonucleotide-treated group suggest that
extended treatment periods will have no sufficient effect
because of the compensatory disease-mediating IL-18
upregulation. Therefore, future studies should evaluate a
combination therapy using Stat4 and IL-18 blockade.
In conclusion, Stat4-independent factors can drive auto-
immune lupus nephritis in Stat4/MRL-Faslpr mice, while
blocking Stat4 temporarily in advanced nephritis can
ameliorate disease suggesting time-dependent compensatory
proinflammatory mechanisms. The AS oligonucleotide
treatment to block Stat4 in mice with lupus-like disease
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Figure 7 | Interleukin (IL)-18 elicits renal injury independent of IL-12 and IL-23 in MRL/MpJ-Faslpr/Faslpr (MRL-Faslpr) mice.
(a) Leukocytes are increased at the site of implantation and in the kidney following ‘IL-18-carrier cell’ implantation in IL-12/IL-23/ and
IL-12p40þ /þMRL-Faslpr mice, evaluated by immunostaining for T cells (CD4þ , CD8þ , and B220þ ) and Mø (F4/80þ ). We evaluated the
accumulation of infiltrating leukocytes extending from the subcapsular site to the renal cortex and the infiltrating intrarenal leukocytes
glomerular, interstitial, and perivascular. Representative microphotographs of the implantation site and the interstitial/glomerular intrarenal
area are shown, magnification  20. (b) Loss of renal function is accelerated following ‘IL-18-carrier cell’ implantation in IL-12p40/ and
IL-12p40þ /þ MRL-Faslpr mice comparable to loss of renal function of a MRL-Faslpr mouse at 5 months of age. We evaluated renal function
by measuring (1) proteinuria semi-quantitatively, (2) serum blood urea nitrogen (BUN); dotted line is BUN levels in healthy MRL-Faslpr
(2 months of age) controls. Data are the mean±s.e.m.
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suggests a clinically relevant therapy that should be further
investigated for potential and immediate benefits to human
SLE patients.
MATERIALS AND METHODS
Generation of Stat4/MRL-Faslpr mice
To investigate the influence of Stat4 in early stages of murine SLE,
we generated Stat4-deficient (/) MRL-Faslpr mice. MRL-Faslpr
mice and Stat4/ BALB/c mice were purchased from the Jackson
Laboratory (Bar Harbor, Maine), and Stat4/ MRL-Faslpr mice
were derived by a series of genetic backcrosses using the
backcross–intercross scheme. MRL-Faslpr mice were mated with
Stat4/ Balb/c mice to yield heterozygous F1 offspring. We
intercrossed F1 mice and screened the progeny by PCR amplification
of tail genomic DNA for the Faslpr mutation (primer: WT sense
50-CCAACTCAGACAGCAACTGG-30, AS 50-GCTCTTTGAGCAGG
GATG-30) and Stat4 (using the linked neomycin resistance (neo)
gene, primer: neo sense: 50-ATTGAACAAGATTTGCAC-30, neo
AS: 50-CGTCCAGATCATCCTGATC-30). Double homozygous
(Faslpr/Faslpr Stat4/) N1F1 progeny were backcrossed with MRL-
Faslpr/Faslpr mice. B1 progeny, homozygous for the Faslpr mutation
and heterozygous for the Stat4, was intercrossed, and mice
homozygous for the Stat4/ mutation were selected by PCR typing
for continued backcrossing. After five generations of backcross
matings, this breeding scheme generated a colony
of MRL-Faslpr mice (495–97.8% MRL background) homozygous
and heterozygous for the mutated Stat4. We analyzed the F6
generation as it was previously established that there are sufficient
MRL-Faslpr background genes even by the F3 generation to result in
phenotypic changes characteristic of the MRL-Faslpr strain.33
Moreover, we performed a genome scan to ensure 495% MRL
background in used mice (Supplementary Figure 1). MRL-Faslpr
Stat4þ /þ (n¼ 22) and MRL-Faslpr Stat4/ (n¼ 13) were under
observation for 6 months to determine the effect of Stat4 deficiency
in disease development. MRL-Faslpr Stat4þ /þ mice were littermate
controls. IL-12p40-deficient (/) MRL-Faslpr mice were derived by
a series of 10 genetic intercross/backcross matings as previously
described.10
The use of mice in this study was reviewed and approved by the
Standing Committee on Animals at the University of Mainz. All of
the animal experiments in this study were performed in Germany.
Mice were bred and housed in our pathogen-free facilities at
Johannes Gutenberg University in Mainz.
Treatment with oligonucleotides
To investigate the effect of Stat4 blockade in mice with manifest
lupus nephritis, we treated MRL-Faslpr mice with AS oligonucleo-
tides, MS oligonucleotides (each kindly provided by Professor
Neurath, Mainz, Germany) or phosphate-buffered saline (control).34
MRL-Faslpr mice were purchased from the Jackson Laboratory.
We started oligonucleotide treatment at 5 months of age.
Oligonucleotides were administered intraperitoneally three times
per week for 3 weeks. Each group consisted of 12 mice.
Renal function
Proteinuria and hematuria were measured with a dipstick (Multistix:
Bayer Diagnostics, Bridgend, UK). We assessed urinary protein
levels and hematuria only semiquantitatively on a monthly basis
beginning at 2 months of age. On the days of analysis, dipstick
proteinuria measurements were made in individual mouse in the
morning and repeated in the evening. If the measurements were
inconsistent, the mouse was reassessed on the following day and in
addition, all mice were reassessed twice a week.33 We measured
BUN levels using a colorimetric analysis kit (Infinity, Thermo
Electron, Melbourne, Victoria, Australia), and serum creatinine
using the creatinine reagent kit and Creatinine Analyzer 2 (Beckman
Coulter, Galway, Ireland) according to the manufacturer’s
instructions.
Cytokine levels and IgG subclasses
Levels of IL-18, INF-g, IL-12, and IL-1b in serum were quantified
using the enzyme-linked immunosorbent assay technique according
to the manufacturer’s instructions (OpEIA mouse kit, BD
Bioscience, San Jose´, CA). IgG subclasses: levels of IgG and its
subclasses (IgG1, IgG2a, IgG2b, IgG3) have been determined by
enzyme-linked immunosorbent assay technique (Alkaline phospha-
tase-based enzyme-linked immunosorbent assay, SouthernBiotech,
Birmingham, AL)
Body weight, organ weight, lymph nodes
Body weight was measured once a week. After killing, organ weight
was measured and the size of lymph nodes was scored (0¼ none,
0.5¼ small, 1¼moderate, 2¼ large, 3¼ very large).
Histopathology
We fixed kidneys in 10% neutral-buffered formalin for 24 h, and
stained paraffin sections (4mm) with periodic acid-Schiff ’s reagent.
We evaluated kidney pathology as previously described.33 Briefly,
we assessed glomerular pathology by scoring each glomerulus on a
semiquantitative scale: 0¼ normal (35–40 cells/glomerular cross-
sections (gcs)); 1¼mild (glomeruli with few lesions showing slight
proliferative changes, mild hypercellularity (41–50 cells/gcs));
2¼moderate (glomeruli with moderate hypercellularity (51–60
cells/gcs), including segmental and/or diffuse proliferative changes,
hyalinosis); 3¼ severe (glomeruli with segmental or global sclerosis
and/or severe hypercellularity (460 cells/gcs), necrosis, crescent
formation). We scored 20 gcs per kidney. Interstitial/tubular
pathology was assessed semiquantitatively on a scale of 0–3 in
10 randomly selected high-power fields (hpf). We determined the
largest and average number of infiltrates and damaged tubules, and
adjusted the grading system accordingly: 0¼ normal, 1¼mild,
2¼moderate, 3¼ severe. Perivascular cell accumulation was deter-
mined semiquantitatively by scoring the number of cell layers
surrounding the majority of vessel walls (score: 0¼ none, 1¼o5
cell layers, 2¼ 5–10 cell layers, 3¼410 cell layers).
Immunostaining
Kidney tissue was processed and stained for the presence of F4/80,
CD4, CD8, and B220, as previously described for the kidney.35 We
determined the number of positive cells in 10 randomly selected hpf.
In vitro culture
To check the specificity and efficacy of the oligonucleotides used in
the in vivo treatment, splenocytes of BALB/c and MRL-Faslpr mice
were isolated as previously descried26 and stimulated with IL-12,
IL-18 (R&D Systems, Minneapolis, MN), goat anti-IL-18 (Santa
Cruz Biotechnologies, Santa Cruz, CA), with or without the
addition of either Stat4 AS or Stat4 MS oligonucleotides (kindly
provided by Professor Dr Neurath, Mainz, Germany, and modified
by Carl Roth GmbH, Karlsruhe, Germany).34
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Retrovirus-mediated cytokine gene transfer into
cultured TECs
We isolated and cultured TECs derived from MRL-Faslpr mice at 2–3
months of age, as previously reported.16 For the retroviral gene
transfer, we used a helper-free retrovirus packaging cell line (PT67;
Clontech Laboratories, Mountain View, CA). The complete IL-18
precursor complementary DNAwas kindly provided by Professor Dr
Neurath (Johannes Gutenberg University of Mainz, Germany). This
recombination-incompetent retroviral vector (pLEGFP-N1, Clon-
tech Laboratories Inc.) containing the murine IL-18 gene was
introduced into PT67 cells containing proviral sequences necessary
for the ‘packing’ (for example, encapsidation) of the virus.36 Using
the supernatant of PT67-IL-18 cells, we infected TECs with the
recombinant retrovirus in the presence of polybrene. To verify gene
transfer into TECs, (1) vector-containing cells were detected
by fluorescence (green fluorescent protein, part of the vector)
(2) neomycin-resistant TECs were selected using G418 (Sigma,
St Louis, MO; 800mg/ml), and (3) IL-18 was measured in
supernatants collected 5 days after infection by enzyme-linked
immunosorbent assay. For control experiments, TECs were infected
with the pLEGFP-N1 retroviral vector without the gene of interest.
TECs genetically modified to express a gene are termed ‘carrier cells’,
for example, TEC-producing IL-18 as ‘IL-18-carrier cells’; TECs
containing the vector without insert as ‘carrier cells’.
Delivery of TECs under the renal capsule
We placed ‘carrier cells’ under the renal capsule of MRL-Faslpr
IL-12/IL-23/MRL-Faslpr and MRL
þ /þ
mice at 2 months of
age. We tested the viability of the TECs immediately before
implantation using trypan blue (Invitrogen, Carlsbad, CA) exclu-
sion staining, viability was 490%. The animals were anesthetized
and the left kidney was exposed through a left flank incision.
‘Carrier cells’ (1 106 in 50 ml of Hanks balanced salt solution w/o
Ca) (Sigma) were micropipetted under the capsule of the dorsal
surface of the left kidney.
Statistical analysis
Data were compared using SPSS 14 (Chicago, IL). The significance
was determined by Student’s unpaired t-test or Mann–Whitney
U-test. P-values o0.05 were considered significant.
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